Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Blackbird to raise £2.2m to fund product development, shares drop

(Sharecast News) - Shares in cloud video editing platform Blackbird dropped sharply on Thursday after the company announced a £2.2m fundraising at a heavy discount to the share price as it raises cash to accelerate its flagship product, elevate.io. Elevate.io is Blackbird's browser-based video-editing tool for content creators and corporate users, designed to be the "Figma for video editing", according to the company.

The funds raised will help achieve product market fit for the product, concluding the SaaS development cycle and accelerating the go-to-market plan, as well as go towards general working capital.

The fundraising includes a £1.865m share placing, representing 13.5% of the enlarged share capital, a subscription for certain members of the board and senior management to raise £0.135m, and a retail offer to raise £0.2m.

All three actions were made at a price of 3p per share, a 29.4% discount to Blackbird's 4.25p closing price on Wednesday. As a result, the stock had dropped nearly 26% to 3.16p by 0933 BST.

"I am pleased to announce that elevate.io has shown strong early growth metrics since the launch of the Creator Plan in February 2025," said executive chair Ian McDonough.

"The fundraise announced today will support elevate.io through its Product Market Fit phase, ahead of scaling up. Our vision for elevate.io is ambitious, transformative and on track. We have the right technology and the right team in place to succeed."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.